Moberg Pharma AB (FRA:MB8) Beneish M-Score: -2.32 (As of Jun. 26, 2026)


FRA:MB8 Moberg Pharma AB FRA:MB8
59 GF Score
Price €0.79
GF Value €1.09
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB Beneish M-Score?

Moberg Pharma AB FRA:MB8 -2.95% 59 Beneish M-Score is -2.32 as of Jun. 26, 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 59/100 and a GF Value™ of €1.09. The stock has 1 warning sign investors should review. Among 911 Drug Manufacturers companies, Moberg Pharma AB ranks worse than 63.45% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.32 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Moberg Pharma AB's Beneish M-Score or its related term are showing as below:

FRA:MB8' s Beneish M-Score Range Over the Past 10 Years
Min: -3.59   Med: -2.63   Max: 17.67
Current: -2.32

During the past 13 years, the highest Beneish M-Score of Moberg Pharma AB was 17.67. The lowest was -3.59. And the median was -2.63.


Moberg Pharma AB Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Beneish M-Score Chart

Moberg Pharma AB Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec21 Dec22 Dec23 Dec24
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Moberg Pharma AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.33 -3.55 -3.59 -0.51 -2.32

FRA:MB8 vs ZTS: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Moberg Pharma AB Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Beneish M-Score falls into.


FRA:MB8
59GF Score
Moberg Pharma AB FRA:MB8
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moberg Pharma AB Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Moberg Pharma AB for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8607+0.528 * 1.1371+0.404 * 1.0994+0.892 * 1.1675+0.115 * 2.4788
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.005+4.679 * -0.019463-0.327 * 1.0844
=-2.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €0.62 Mil.
Revenue was 0.457 + 0.19 + 0.364 + 0.327 = €1.34 Mil.
Gross Profit was 0.302 + 0.092 + 0.22 + 0.154 = €0.77 Mil.
Total Current Assets was €21.82 Mil.
Total Assets was €63.45 Mil.
Property, Plant and Equipment(Net PPE) was €0.22 Mil.
Depreciation, Depletion and Amortization(DDA) was €0.15 Mil.
Selling, General, & Admin. Expense(SGA) was €2.88 Mil.
Total Current Liabilities was €1.66 Mil.
Long-Term Debt & Capital Lease Obligation was €0.04 Mil.
Net Income was -0.117 + -1.172 + -0.392 + -0.671 = €-2.35 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = €0.00 Mil.
Cash Flow from Operations was -0.321 + 0.139 + -0.751 + -0.184 = €-1.12 Mil.
Total Receivables was €0.62 Mil.
Revenue was 0.353 + 0.089 + 0.34 + 0.364 = €1.15 Mil.
Gross Profit was 0.234 + -0.012 + 0.285 + 0.241 = €0.75 Mil.
Total Current Assets was €25.71 Mil.
Total Assets was €64.16 Mil.
Property, Plant and Equipment(Net PPE) was €0.37 Mil.
Depreciation, Depletion and Amortization(DDA) was €26.21 Mil.
Selling, General, & Admin. Expense(SGA) was €2.45 Mil.
Total Current Liabilities was €1.39 Mil.
Long-Term Debt & Capital Lease Obligation was €0.20 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(0.622 / 1.338) / (0.619 / 1.146)
=0.464873 / 0.54014
=0.8607

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.748 / 1.146) / (0.768 / 1.338)
=0.652705 / 0.573991
=1.1371

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (21.816 + 0.224) / 63.454) / (1 - (25.706 + 0.367) / 64.164)
=0.652662 / 0.593651
=1.0994

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1.338 / 1.146
=1.1675

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(26.205 / (26.205 + 0.367)) / (0.148 / (0.148 + 0.224))
=0.986188 / 0.397849
=2.4788

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2.876 / 1.338) / (2.451 / 1.146)
=2.149477 / 2.138743
=1.005

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0.041 + 1.662) / 63.454) / ((0.195 + 1.393) / 64.164)
=0.026838 / 0.024749
=1.0844

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-2.352 - 0 - -1.117) / 63.454
=-0.019463

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Moberg Pharma AB has a M-score of -2.30 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.32 mean?
Moberg Pharma AB (FRA:MB8) has a Beneish M-Score of -2.32 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Moberg Pharma AB and its competitors. According to the industry distribution chart, Moberg Pharma AB ranks #578 out of 911 companies in the Drug Manufacturers industry, placing it in the top 63.4%.
Is Moberg Pharma AB's Beneish M-Score too high?
Moberg Pharma AB's current Beneish M-Score is -2.32. Based on the distribution chart, Moberg Pharma AB ranks #578 out of 911 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Moberg Pharma AB has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Beneish M-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #578 out of 911 companies for Beneish M-Score. This places Moberg Pharma AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current Beneish M-Score is -2.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Moberg Pharma AB (FRA:MB8) has a current Beneish M-Score of -2.32. The stock's GF Value™ is €1.09, compared to a current price of €0.79 — trading 27.6% below its estimated fair value. The current Beneish M-Score is -2.32. Moberg Pharma AB's overall GF Score™ is 59/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Beneish M-Score is -2.32 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.79 is trading 27.6% below its estimated GF Value™ of €1.09.

Key valuation signals for FRA:MB8:

  • Beneish M-Score: -2.32
  • GF Value™: €1.09 vs. price of €0.79 (27.6% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Moberg Pharma AB Business Description

Other Exchanges MBGPF:USAMOB:Sweden
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for FRA:MB8

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.79
Price
€1.09
GF Value